Progeneer Looks To Disrupt Cell-Free Protein Synthesis Landscape
- Individualized Oncovaccine Against BCL

Executive Summary

Progeneer CEO Chul Kim talks to Scrip about how the Korean bioventure aims to make a difference in cell-free protein synthesis and vaccine adjuvant
systems to become a game changer...

* Interview with Scrip, click here for the full article